NCT03818191View on ClinicalTrials.gov

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

PHASE4CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

November 4, 2023

Study Completion Date

November 4, 2023

Conditions
Alcohol Use Disorder
Interventions
DRUG

Acamprosate

The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.

OTHER

Placebo

The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.

Trial Locations (3)

55012

Hazelden Betty Ford Foundation, Center City

55905

Mayo Clinic in Rochester, Rochester

97132

Hazelden Betty Ford Foundation, Newberg

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Mayo Clinic

OTHER

NCT03818191 - Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome | Biotech Hunter | Biotech Hunter